Auxo Firm Directory · Independent Research Profile

Bailey & Company

Bailey & Company advises buyside and sellside clients on controlled transactions in and around the lower-middle-market healthcare space. Its stated services include M&A, equity and debt capital raises, private placements, and financial restructurings.

Key takeaway

What stands out about Bailey & Company

Bailey & Company focuses on middle-market healthcare transactions and states that it works with buyside and sellside clients. Its public services include M&A advisory, equity and debt capital raises, private placements, and financial restructurings, while its growth-capital offering involves $10-$50 million capital raises.[1][2][3][6][7][8]

What does Bailey & Company do?

Bailey & Company is a Nashville-based investment bank focused on strategic transactions in the middle-market healthcare sector. The firm lists its headquarters at 5511 Virginia Way, Suite 200, Brentwood, Tennessee.

Its stated process is one-to-one and personalized, with senior-led teams engaged throughout the transaction process. The firm describes its approach as based on relationships, platform, and insights, including access to institutional investors and industry executives.[1][2][4]

Bailey & Company offers mergers and acquisitions advisory, equity and debt capital raises, private placements, and financial restructurings. It also states that it delivers growth capital involving $10-$50 million capital raises.

The firm says it works with buyside and sellside clients on controlled transactions in and around the lower-middle-market healthcare space.[3]

Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.

Public size / criteria information
Bailey & Company describes its market as the middle-market and lower-middle-market healthcare space and states that its growth-capital transactions involve $10-$50 million capital raises. The cited services page does not publish a universal revenue, EBITDA, enterprise-value, or minimum-size threshold for advisory engagements.[3]

What should a business owner evaluate before hiring Bailey & Company?

For an owner evaluating a sale or recapitalization, Bailey & Company’s public positioning centers on healthcare services, healthcare IT and tech-enabled services, payer services, and pharma services, medtech, and life sciences. The firm states that it serves the middle-market and lower-middle-market healthcare space and works with both buyside and sellside clients.

Its disclosed transaction record includes strategic acquisitions and a recapitalization, with lead bankers named on the cited assignments. An owner should confirm which legal entity would contract for and execute the engagement, the proposed fee and expense provisions, the contemplated transaction structure, the relevant experience of the proposed team, the expected buyer universe, conflicts, and the information required for any valuation view or marketing plan.[1][3][4][6][7][8][9][10]

01

Which legal entity would contract for and execute the engagement

Bailey & Company states that securities are offered by and conducted through Bailey & Co. Securities, LLC, while the parent entity is Bailey & Company Parent, LLC, doing business as Bailey & Company.[1]
02

What are the proposed success fee, retainer, minimum fee, expense, tail, and termination provisions

The cited Andros, DialysisPPO, and HealthCorum transaction pages do not disclose fee terms, and the cited services page does not publish a universal minimum-size threshold for advisory engagements.[3][6][7][8]
03

Which recent comparable transactions were led by the proposed team

Bailey & Company identifies lead bankers on recent Andros, DialysisPPO, HealthCorum, and Ascendia Autism Care assignments, including both acquisitions and a recapitalization.[6][7][8][9]

What size transactions and clients does Bailey & Company focus on?

Bailey & Company publicly lists healthcare services; healthcare IT and tech-enabled services; payer services; and pharma services, medtech, and life sciences as industries it serves.[4]

Bailey & Company’s official transaction pages identify several 2026 assignments. In September 2026, Andros was acquired by Medallion, with Tim Scallen and Cray Yoo identified as lead bankers. In July 2026, DialysisPPO was acquired by ClaimsBridge, with Patrick Keavy identified as lead banker. Also in July 2026, HealthCorum was acquired by The Difference Card, with Patrick Keavy identified as lead banker.

In June 2026, Ascendia Autism Care was recapitalized by Cathay Capital, with Phillip Knotts and Russell Bryan identified as lead bankers.

The firm’s transaction archive states that Bailey & Company has completed more than 200 successful transactions representing $17 billion in transactional value, while noting that the record includes transactions completed by senior professionals at previous firms.[5][6][7][8][9]

The firm’s stated transaction focus includes mergers and acquisitions, equity and debt capital raises, private placements, and financial restructurings. Its services description also identifies growth-capital transactions involving $10-$50 million capital raises and work with both buyside and sellside clients.[3]

What does Bailey & Company publicly disclose about fees, process and engagement terms?

The cited services page does not publish a universal revenue, EBITDA, enterprise-value, or minimum-size threshold for advisory engagements.

The cited Andros, DialysisPPO, and HealthCorum transaction pages do not disclose transaction value, fee terms, financing terms, or consideration structure for those transactions.[3][6][7][8]

Bailey & Company states that securities are offered by and conducted through Bailey & Co. Securities, LLC, which it describes as an SEC-registered broker-dealer and a member of FINRA and SIPC. The firm states that Bailey & Co. Securities, LLC is wholly owned by Bailey & Company Parent, LLC, doing business as Bailey & Company.

An SEC-filed annual report identifies Bailey & Co. Securities, LLC as a broker-dealer with its principal office at 5511 Virginia Way, Suite 200, Brentwood, Tennessee.[1][10]

Bailey & Company describes its process as one-to-one, personalized, and senior-led, with senior teams engaged throughout the transaction process. It also describes a relationship-driven approach involving institutional investors and industry executives and customized transaction processes.[1][4]

Questions to ask before hiring Bailey & Company

Which legal entity would contract for and execute the engagement?
Bailey & Company states that securities are offered by and conducted through Bailey & Co. Securities, LLC, while the parent entity is Bailey & Company Parent, LLC, doing business as Bailey & Company.[1]
What are the proposed success fee, retainer, minimum fee, expense, tail, and termination provisions?
The cited Andros, DialysisPPO, and HealthCorum transaction pages do not disclose fee terms, and the cited services page does not publish a universal minimum-size threshold for advisory engagements.[3][6][7][8]
Which recent comparable transactions were led by the proposed team?
Bailey & Company identifies lead bankers on recent Andros, DialysisPPO, HealthCorum, and Ascendia Autism Care assignments, including both acquisitions and a recapitalization.[6][7][8][9]
How broad is the expected buyer universe across strategic acquirers and financial sponsors?
The firm states that it works with buyside and sellside clients and connects clients with institutional investors and industry executives.[1][3]
Will the firm recommend a sale, recapitalization, minority investment, or debt or equity financing process?
Bailey & Company publicly describes M&A advisory, equity and debt capital raises, private placements, financial restructurings, growth capital, and recapitalization activity among its stated services or disclosed transactions.[3][9]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Official website / firm overview
  3. Services / capabilities
  4. Industry / market focus
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
  9. Transaction / portfolio evidence
  10. SEC filing / regulatory record
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.